<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>30730_111</messagenumb>
		<messagesenderidentifier>VERTEXP2</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151731</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>US-VERTEX PHARMACEUTICALS INC.-2012-026553</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121220</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130123</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-VERTEX PHARMACEUTICALS INC.-2012-026553</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
			<studyname>Solicited Program</studyname>
			<sponsorstudynumb>Solicited - CVS Caremark</sponsorstudynumb>
			<observestudytype>3</observestudytype>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>VERTEXP2</senderorganization>
			<senderdepartment>Global Patient Safety</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>Sean</sendergivename>
			<senderfamilyname>Darcy</senderfamilyname>
			<senderstreetaddress>130 Waverly Street</senderstreetaddress>
			<sendercity>Cambridge</sendercity>
			<senderstate>MA</senderstate>
			<senderpostcode>02139</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<senderemailaddress>VRTXGPS_SubmissionTracking@vrtx.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>Office of Surveillence and Epidemiology</receiverdepartment>
			<receivertitle>Mr.</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receiverfax>3019183134</receiverfax>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>UNKNOWN</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19671121</patientbirthdate>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hepatitis C</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Internal bleeding</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Bleeding</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Haemorrhage</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121215</reactionstartdate>
				<reactionfirsttime>50</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Anemia / low hgb</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Anemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Anaemia</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121215</reactionstartdate>
				<reactionfirsttime>50</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Low white blood cell</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>White blood cell count low</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>White blood cell count decreased</reactionmeddrapt>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Itchy rash</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Itchy rash</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Rash pruritic</reactionmeddrapt>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>VX-950 (Telaprevir)</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>201917</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Vertex Pharmaceuticals Inc.</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121026</drugstartdate>
				<drugstartperiod>50</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20130118</drugenddate>
				<drugtreatmentduration>85</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>VX-950</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemorrhage</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemorrhage</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rash pruritic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rash pruritic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>White blood cell count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>White blood cell count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>RIBAVIRIN</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121026</drugstartdate>
				<actiondrug>2</actiondrug>
				<activesubstance>
					<activesubstancename>RIBAVIRIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>RIBAVIRIN</medicinalproduct>
				<drugstructuredosagenumb>600</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>600 mg, qd</drugdosagetext>
				<actiondrug>2</actiondrug>
				<activesubstance>
					<activesubstancename>RIBAVIRIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PEGASYS</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121026</drugstartdate>
				<actiondrug>2</actiondrug>
				<activesubstance>
					<activesubstancename>PEGINTERFERON ALFA-2A</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PEGASYS</medicinalproduct>
				<drugstructuredosagenumb>135</drugstructuredosagenumb>
				<drugstructuredosageunit>004</drugstructuredosageunit>
				<drugdosagetext>135 &#xc2b5;g, qw</drugdosagetext>
				<actiondrug>2</actiondrug>
				<activesubstance>
					<activesubstancename>PEGINTERFERON ALFA-2A</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>Hypertension med</medicinalproduct>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugrecurreadministration>3</drugrecurreadministration>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>Cholestrol Meds</medicinalproduct>
				<drugrecurreadministration>3</drugrecurreadministration>
			</drug>
			<summary>
				<narrativeincludeclinical>A solicited serious report of  INTERNAL BLEEDING, ANEMIA was received from a Consumer in UNITED STATES concerning a 45 year old, male patient participating in a monitored therapy program, subsequent to dosing with INCIVEK (telaprevir), ribavirin and peg interferon.

Concomitant medications of the patient included hypertension and cholesterol medications. Past medical history was not provided.

On 26-Oct-2012, the patient received Incivek (telaprevir) (oral, tablet), ribavirin and peg interferon for Hepatitis C. The patient received Incivek (telaprevir), ribavirin and peg interferon for approximately 50 days before the onset of the events.

On 15-Dec-2012, the patient developed internal bleeding and anemia. The patient stated he spent 4 days in the hospital. It was reported that hepatitis C medications were held for 4 days while hypertension and cholesterol medications were adjusted. HCV triple therapy was maintained.

The events of internal bleeding and anemia had not resolved at the time of the report.

Follow up information was received on 23-Jan-2013. New AE terms reported were LOW WHITE BLOOD CELL and ITCHY RASH. The event term of ANEMIA was updated to ANEMIA/ LOW HGB. His ribavirin dose was decreased to 600mg/day and peginterferon dose was reduced to 135microgram/week.</narrativeincludeclinical>
				<sendercomment>Serious hemorrhage and non-serious white blood cell count decreased are considered unexpected for Incivek (telaprevir), while serious anemia and non-serious pruritic rash are expected. Limited information (lack of event details, site of hemorrhage, medical history, coagulation status, concomitant medications) precludes a meaningful medical assessment for hemorrhage. Contributing factors for anemia may include the internal bleeding and possibly concomitant ribavirin.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
